vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and Revolve Group, Inc. (RVLV). Click either name above to swap in a different company.
Revolve Group, Inc. is the larger business by last-quarter revenue ($324.4M vs $183.1M, roughly 1.8× Amphastar Pharmaceuticals, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs 5.7%, a 7.6% gap on every dollar of revenue. On growth, Revolve Group, Inc. posted the faster year-over-year revenue change (10.4% vs -1.8%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $-13.3M). Over the past eight quarters, Revolve Group, Inc.'s revenue compounded faster (9.5% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Revolve Theatre Company is a Henley-on-Thames based theatre company specialising in political and Shakespearean plays. The company is owned by Oliver Dench, Joe Morris and Tom Smith.
AMPH vs RVLV — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $324.4M |
| Net Profit | $24.4M | $18.6M |
| Gross Margin | 46.8% | 53.3% |
| Operating Margin | 19.4% | 6.3% |
| Net Margin | 13.3% | 5.7% |
| Revenue YoY | -1.8% | 10.4% |
| Net Profit YoY | -35.7% | 50.4% |
| EPS (diluted) | $0.51 | $0.27 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $324.4M | ||
| Q3 25 | $191.8M | $295.6M | ||
| Q2 25 | $174.4M | $309.0M | ||
| Q1 25 | $170.5M | $296.7M | ||
| Q4 24 | $186.5M | $293.7M | ||
| Q3 24 | $191.2M | $283.1M | ||
| Q2 24 | $182.4M | $282.5M | ||
| Q1 24 | $171.8M | $270.6M |
| Q4 25 | $24.4M | $18.6M | ||
| Q3 25 | $17.4M | $21.2M | ||
| Q2 25 | $31.0M | $10.2M | ||
| Q1 25 | $25.3M | $11.8M | ||
| Q4 24 | $38.0M | $12.3M | ||
| Q3 24 | $40.4M | $11.0M | ||
| Q2 24 | $37.9M | $15.4M | ||
| Q1 24 | $43.2M | $10.9M |
| Q4 25 | 46.8% | 53.3% | ||
| Q3 25 | 51.4% | 54.6% | ||
| Q2 25 | 49.6% | 54.1% | ||
| Q1 25 | 50.0% | 52.0% | ||
| Q4 24 | 46.5% | 52.5% | ||
| Q3 24 | 53.3% | 51.2% | ||
| Q2 24 | 52.2% | 54.0% | ||
| Q1 24 | 52.4% | 52.3% |
| Q4 25 | 19.4% | 6.3% | ||
| Q3 25 | 13.2% | 7.1% | ||
| Q2 25 | 24.2% | 5.8% | ||
| Q1 25 | 21.9% | 5.0% | ||
| Q4 24 | 24.2% | 3.9% | ||
| Q3 24 | 29.8% | 5.0% | ||
| Q2 24 | 30.3% | 5.8% | ||
| Q1 24 | 27.9% | 3.4% |
| Q4 25 | 13.3% | 5.7% | ||
| Q3 25 | 9.0% | 7.2% | ||
| Q2 25 | 17.8% | 3.3% | ||
| Q1 25 | 14.8% | 4.0% | ||
| Q4 24 | 20.4% | 4.2% | ||
| Q3 24 | 21.1% | 3.9% | ||
| Q2 24 | 20.8% | 5.4% | ||
| Q1 24 | 25.1% | 4.0% |
| Q4 25 | $0.51 | $0.27 | ||
| Q3 25 | $0.37 | $0.29 | ||
| Q2 25 | $0.64 | $0.14 | ||
| Q1 25 | $0.51 | $0.16 | ||
| Q4 24 | $0.74 | $0.18 | ||
| Q3 24 | $0.78 | $0.15 | ||
| Q2 24 | $0.73 | $0.21 | ||
| Q1 24 | $0.81 | $0.15 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $292.3M |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | $512.5M |
| Total Assets | $1.6B | $765.0M |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $292.3M | ||
| Q3 25 | $276.2M | $315.4M | ||
| Q2 25 | $231.8M | $310.7M | ||
| Q1 25 | $236.9M | $300.8M | ||
| Q4 24 | $221.6M | $256.6M | ||
| Q3 24 | $250.5M | $252.8M | ||
| Q2 24 | $217.8M | $244.7M | ||
| Q1 24 | $289.6M | $273.4M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $512.5M | ||
| Q3 25 | $776.7M | $490.2M | ||
| Q2 25 | $757.5M | $468.6M | ||
| Q1 25 | $751.3M | $453.4M | ||
| Q4 24 | $732.3M | $437.8M | ||
| Q3 24 | $727.7M | $420.8M | ||
| Q2 24 | $713.3M | $405.8M | ||
| Q1 24 | $672.4M | $389.9M |
| Q4 25 | $1.6B | $765.0M | ||
| Q3 25 | $1.7B | $751.3M | ||
| Q2 25 | $1.6B | $722.9M | ||
| Q1 25 | $1.6B | $713.9M | ||
| Q4 24 | $1.6B | $665.5M | ||
| Q3 24 | $1.5B | $670.9M | ||
| Q2 24 | $1.5B | $657.8M | ||
| Q1 24 | $1.6B | $650.0M |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $-10.2M |
| Free Cash FlowOCF − Capex | $24.6M | $-13.3M |
| FCF MarginFCF / Revenue | 13.4% | -4.1% |
| Capex IntensityCapex / Revenue | 4.5% | 1.0% |
| Cash ConversionOCF / Net Profit | 1.35× | -0.55× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $48.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $-10.2M | ||
| Q3 25 | $52.6M | $11.8M | ||
| Q2 25 | $35.6M | $12.6M | ||
| Q1 25 | $35.1M | $45.1M | ||
| Q4 24 | $29.0M | $3.9M | ||
| Q3 24 | $60.0M | $9.1M | ||
| Q2 24 | $69.1M | $-24.7M | ||
| Q1 24 | $55.3M | $38.4M |
| Q4 25 | $24.6M | $-13.3M | ||
| Q3 25 | $47.2M | $7.5M | ||
| Q2 25 | $25.0M | $10.4M | ||
| Q1 25 | $24.4M | $43.4M | ||
| Q4 24 | $16.6M | $2.1M | ||
| Q3 24 | $46.2M | $8.0M | ||
| Q2 24 | $63.1M | $-25.7M | ||
| Q1 24 | $46.5M | $36.7M |
| Q4 25 | 13.4% | -4.1% | ||
| Q3 25 | 24.6% | 2.5% | ||
| Q2 25 | 14.3% | 3.4% | ||
| Q1 25 | 14.3% | 14.6% | ||
| Q4 24 | 8.9% | 0.7% | ||
| Q3 24 | 24.1% | 2.8% | ||
| Q2 24 | 34.6% | -9.1% | ||
| Q1 24 | 27.1% | 13.5% |
| Q4 25 | 4.5% | 1.0% | ||
| Q3 25 | 2.8% | 1.5% | ||
| Q2 25 | 6.1% | 0.7% | ||
| Q1 25 | 6.3% | 0.6% | ||
| Q4 24 | 6.7% | 0.6% | ||
| Q3 24 | 7.2% | 0.4% | ||
| Q2 24 | 3.3% | 0.4% | ||
| Q1 24 | 5.1% | 0.6% |
| Q4 25 | 1.35× | -0.55× | ||
| Q3 25 | 3.03× | 0.56× | ||
| Q2 25 | 1.15× | 1.24× | ||
| Q1 25 | 1.39× | 3.82× | ||
| Q4 24 | 0.76× | 0.32× | ||
| Q3 24 | 1.48× | 0.83× | ||
| Q2 24 | 1.82× | -1.60× | ||
| Q1 24 | 1.28× | 3.53× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
RVLV
| Fashion Apparel | $155.1M | 48% |
| Dresses | $76.4M | 24% |
| Handbags Shoes And Accessories | $67.6M | 21% |
| Beauty | $20.3M | 6% |
| Manufactured Product Other | $5.0M | 2% |
| Breakage On Store Credit And Gift Cards | $900.0K | 0% |
